Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2024 04:15 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC Investor webcast to be held Friday, October...
October 23, 2024 06:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday,...
October 07, 2024 09:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
April 23, 2015 04:00 ET | Source: Metaswitch Networks

ENA Selects Metaswitch to Enhance Its IP Multimedia Communications

LONDON, UNITED KINGDOM and NASHVILLE, TN--(Marketwired - April 23, 2015) - Metaswitch Networks, the world's leading network software provider, announced today that Education Networks of America (ENA),...